Plus latest news & Annals of Oncology articles
Not rendering correctly? View this email as a web page here.

Dear Colleague,

New: ELCC 2016 meeting resources
ESMO Members and event attendees only

This exciting event took place just last week in Geneva and brought together the most important multidisciplinary societies representing thoracic oncology specialists. The objectives of this important Conference were to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.

You can now find all webcasts and presentations online.

Access the resources »

E-Learning-
Optimising the assessment and therapy
of oesophago-gastric junction adenocarcinomas 
ESMO Membership
Read our latest news, access all our meeting resources & take our
E-Learning modules


Updated: ESMO Clinical Practice Guidelines


Cutaneous melanoma is the most common type of melanoma, and UV exposure is one of the main risk factors. The updated ESMO Clinical Practice Guidelines on cutaneous melanoma include information on diagnosis and staging, as well as stage-matched treatment strategies for locoregional and systemic metastatic
(stage IV) disease.

 


New: ESMO E-Learning module


Oesophago-gastric junction adenocarcinoma incidence is increasing. In the educational arena it is usually covered together with gastric cancer so there is little material available focusing on oesophago-gastric junction cancer. The added value of this E-learning module lies in the fact that it is fully dedicated to this topic, and is further enhanced by carefully balanced expertise.

The authors cover epidemiology, definition, classification, staging and risk assessment, as well as practice recommendations for treatment, including curative treatment strategies. 

The module was p
repared by Elisa Fontana and David Cunningham.

 

Annals of Oncology: Advance Access Articles
ESMO members and AoO subscribers

Latest Annals of Oncology advanced access article: 

Latest News
ESMO Members only

Third-line Pazopanib Improves PFS For Advanced TKI-Refractory GIST
Third-line pazopanib may extend progression-free survival in advanced gastrointestinal stromal tumours.

Read the full article »


PALOMA-3 Demonstrates QoL Benefits With Palbociclib Plus Fulvestrant
Patient-reported outcomes for quality of life favour addition of palbociclib to fulvestrant for hormone receptor-positive, HER2-negative, metastatic breast cancer.

Read the full article »

Farletuzumab Tested For Recurrent Platinum-Sensitive Ovarian Cancer
Farletuzumab fails to improve survival outcomes over platinum-based chemotherapy alone in ovarian cancer patients overall but may have potential for women with a low CA-125 value.

Read the full article »

 


Tumour Knowledge Portal


Tumour Knowledge Portal

The Tumour Knowledge Portal groups ESMO resources together according to the disease or topic area to help you to find all educational content catalogued around your own area of interest, regardless of the type of resource.


Major sponsors:
AstraZeneca, Janssen

Main sponsors:
Amgen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Genomic Health, Lilly, Roche
 

OP Sponsors

Follow us on YouTube Follow us on RSS Follow us on Twitter Follow us on Facebook